M
Marina Cardellini
Researcher at University of Rome Tor Vergata
Publications - 60
Citations - 3561
Marina Cardellini is an academic researcher from University of Rome Tor Vergata. The author has contributed to research in topics: Insulin resistance & Type 2 diabetes. The author has an hindex of 28, co-authored 59 publications receiving 3032 citations. Previous affiliations of Marina Cardellini include Sapienza University of Rome.
Papers
More filters
Journal ArticleDOI
MicroRNA 217 Modulates Endothelial Cell Senescence via Silent Information Regulator 1
Rossella Menghini,Viviana Casagrande,Marina Cardellini,Eugenio Martelli,Alessandro Terrinoni,Francesca Amati,Mariuca Vasa-Nicotera,Arnaldo Ippoliti,Giuseppe Novelli,Gerry Melino,Renato Lauro,Massimo Federici +11 more
TL;DR: The data pinpoint miR-217 as an endogenous inhibitor of SirT1, which promotes endothelial senescence and is potentially amenable to therapeutic manipulation for prevention of endothelial dysfunction in metabolic disorders.
Journal ArticleDOI
Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women.
Lesley Hoyles,José Manuel Fernández-Real,Massimo Federici,Matteo Serino,Matteo Serino,James Abbott,Julie Charpentier,Julie Charpentier,Christophe Heymes,Christophe Heymes,Jèssica Latorre Luque,Elodie Anthony,Richard H. Barton,Julien Chilloux,Antonis Myridakis,Laura Martinez-Gili,José María Moreno-Navarrete,Fadila Benhamed,Vincent Azalbert,Vincent Azalbert,Vincent Blasco-Baque,Vincent Blasco-Baque,Josep Puig,Gemma Xifra,Wifredo Ricart,Christopher Tomlinson,Mark Woodbridge,Marina Cardellini,Francesca Davato,Iris Cardolini,Ottavia Porzio,Ottavia Porzio,Paolo Gentileschi,Frédéric Lopez,Frédéric Lopez,Fabienne Foufelle,Sarah Butcher,Elaine Holmes,Jeremy K. Nicholson,Catherine Postic,Rémy Burcelin,Rémy Burcelin,Marc-Emmanuel Dumas +42 more
TL;DR: It is demonstrated that fecal microbiota transplants and chronic treatment with phenylacetic acid, a microbial product of aromatic amino acids metabolism, successfully trigger steatosis and branched-chain amino acid metabolism.
Journal ArticleDOI
Plasma Concentration of IGF-I Is Independently Associated With Insulin Sensitivity in Subjects With Different Degrees of Glucose Tolerance
Giorgio Sesti,Angela Sciacqua,Marina Cardellini,Maria Adelaide Marini,Raffaele Maio,Marco Vatrano,Elena Succurro,Renato Lauro,Massimo Federici,Francesco Perticone +9 more
TL;DR: Data indicate that IGF-I has the characteristics to be a marker for the insulin resistance syndrome, and suggests that low IGF- I levels may be a useful marker for identifying subjects at risk for cardiovascular disease.
Journal ArticleDOI
Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health.
Ludivine Laurans,Nicolas Venteclef,Yacine Haddad,Mouna Chajadine,Fawaz Alzaid,Sarvenaz Metghalchi,Bruno Sovran,Raphael G. P. Denis,Julien Dairou,Marina Cardellini,J M Moreno-Navarrete,Marjolene Straub,Sarah Jegou,Claire McQuitty,Thomas Viel,Bruno Esposito,Bertrand Tavitian,Jacques Callebert,Serge Luquet,Massimo Federici,José Manuel Fernández-Real,Rémy Burcelin,Jean-Marie Launay,Alain Tedgui,Ziad Mallat,Ziad Mallat,Harry Sokol,Harry Sokol,Harry Sokol,Soraya Taleb +29 more
TL;DR: It is shown that obesity is associated with an increase of intestinal indoleamine 2,3-dioxygenase activity, which shifts tryptophan metabolism from indole derivative and interleukin-22 production toward kynurenine production, which suggests indoleamines 2, 3-diaxgenase as a potential therapeutic target.
Journal ArticleDOI
The E23K Variant of KCNJ11 Encoding the Pancreatic β-Cell Adenosine 5′-Triphosphate-Sensitive Potassium Channel Subunit Kir6.2 Is Associated with an Increased Risk of Secondary Failure to Sulfonylurea in Patients with Type 2 Diabetes
Giorgio Sesti,Emanuela Laratta,Marina Cardellini,Francesco Andreozzi,Silvia Del Guerra,Concetta Irace,Agostino Gnasso,M Grupillo,Renato Lauro,Marta Letizia Hribal,Marta Letizia Hribal,Francesco Perticone,Piero Marchetti +12 more
TL;DR: The data suggest that the E23K variant in KCNJ11 may influence the variability in the response of patients to sulfonylureas, thus representing an example of pharmacogenetics in type 2 diabetes.